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OBJECTIVE—Metreleptin has been efﬁcacious in improving
metabolic control in patients with lipodystrophy, but its efﬁcacy
has not been tested in obese patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS—We studied the role
of leptin in regulating the endocrine adaptation to long-term
caloric deprivation and weight loss in obese diabetic subjects
over 16 weeks in the context of a double-blinded, placebo–
controlled, randomized trial. We then performed detailed inter-
ventional and mechanistic signaling studies in humans in vivo,
ex vivo, and in vitro.
RESULTS—In obese patients with diabetes, metreleptin admin-
istration for 16 weeks did not alter body weight or circulating
inﬂammatory markers but reduced HbA1c marginally (8.01 6
0.93–7.96 6 1.12, P = 0.03). Total leptin, leptin-binding protein,
and antileptin antibody levels increased, limiting free leptin avail-
ability and resulting in circulating free leptin levels of ;50 ng/mL.
Consistent with clinical observations, all metreleptin signaling
pathways studied in human adipose tissue and peripheral blood
mononuclear cells were saturable at ;50 ng/mL, with no major
differences in timing or magnitude of leptin-activated STAT3
phosphorylation in tissues from male versus female or obese
versus lean humans in vivo, ex vivo, or in vitro. We also observed
for the ﬁrst time that endoplasmic reticulum (ER) stress in hu-
man primary adipocytes inhibits leptin signaling.
CONCLUSIONS—In obese patients with diabetes, metreleptin
administration did not alter body weight or circulating inﬂam-
matory markers but reduced HbA1c marginally. ER stress and the
saturable nature of leptin signaling pathways play a key role in the
development of leptin tolerance in obese patients with diabetes.
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M
etreleptin has consistently been shown to
dramatically improve insulin resistance and
HbA1c in several clinical trials involving
hypoleptinemic subjects with lipodystrophy,
hypoleptinemia, insulin resistance, and the metabolic syn-
drome (1). No prior study has evaluated in detail the effect
of metreleptin in obese subjects, with garden variety di-
abetes, obesity, and high circulating leptin levels, who are
presumably resistant or tolerant to the effects of leptin (2).
Furthermore, no prior study has evaluated mechanisms
underlying such leptin tolerance.
In the context of a large, randomized, placebo–controlled
trial, we examined for the ﬁrst time the efﬁcacy of metre-
leptin in regulating body weight, glycemic control, and
immune function in hyperleptinemic obese subjects with
type 2 diabetes. We subsequently examined whether the
observed suboptimal efﬁcacy of circulating leptin in reg-
ulating adiposity and immune function in obese diabetic
individuals is attributable to speciﬁc, identiﬁable mecha-
nisms at the cellular and molecular level. In this respect,
we methodically explored mechanisms previously shown
to underlie other hormone resistance syndromes, e.g., in-
sulin resistance or underlying immunogenicity seen with
use of other biologics. To further elucidate the role of leptin
in regulating human adiposity and immune function and to
study potential mechanisms underlying the development of
leptin resistance or tolerance, we then performed detailed
interventional and mechanistic signaling studies in humans
in vivo, ex vivo, and in vitro.
More speciﬁcally, we ﬁrst discovered that levels of
leptin-binding protein (LBP) and antibodies against metre-
leptin increased in response to metreleptin treatment,
limiting circulating free leptin to ;50 ng/mL despite total
leptin levels of ;982.7 ng/mL in obese diabetic subjects.
We then proceeded to study whether mechanisms that
have been described to affect leptin signaling and thus
leptin resistance in mice, i.e., endoplasmic reticulum (ER)
stress (3–6), are also operative in humans. Subsequently,
we investigated intracellular leptin signaling in vivo in re-
sponse to metreleptin administration in lean and obese
subjects by comparatively studying metreleptin signaling
in human adipose tissue (hAT) and human peripheral
blood mononuclear cells (hPBMCs) from both lean and
obese humans in vivo. Finally, we extended these observa-
tions by studying leptin signaling in vitro and ex vivo in hAT
and hPBMCs from lean and obese subjects to determine
whether neuroendocrine changes induced by metreleptin in
vivo or paracrine mechanisms ex vivo may differentially
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PERSPECTIVES IN DIABETESaffect leptin signaling in humans in vivo versus ex vivo or
in vitro.
RESEARCH DESIGN AND METHODS
Clinical study I: Body weight, metabolic, and immune responses to
metreleptin versus placebo in obese hyperleptinemic subjects with
diabetes. We studied 71 obese subjects (41 male and 30 female; age, 53.3 6 11.4
years; BMI, 33.2 6 3.8 kg/m
2) with diet-controlled type 2 diabetes who gave
written informed consent to participate in the study. Inclusion criteria for
participation in the study included HbA1c between 7 and 11%, BMI between 27
and 40 kg/m
2, and adherence to a stable weight–maintaining diet for at least
4 weeks before the screening evaluation. Subjects could not have taken oral
hypoglycemic agents or insulin in the 12 weeks preceding the screening
evaluation. Subjects were randomized in a 2:1 ratio to receive metreleptin or
placebo, respectively, at a dose of 10 mg twice daily (morning and evening) by
subcutaneous injection for 4 months (16 weeks), resulting in a total daily dose
of 20 mg metreleptin. Blood samples were obtained at baseline (before
metreleptin or placebo treatment) and after 4 and 16 weeks of treatment (with
the exception of nine subjects who received metreleptin and six subjects who
received placebo because of insufﬁcient serum). Samples were stored at 270°C
until assayed for the measurement of leptin, LBP, free leptin, antibody titer,
inﬂammatory marker, and HgbA1c.
Clinical study II: In vivo metreleptin signaling in hAT and hPBMCs from
lean and obese subjects. Normal volunteers were recruited from the com-
munity and screened at the Clinical Research Center at Beth Israel Deaconess
Medical Center (BIDMC). Subjects were excluded if they had a history of any
illness, other thanobesity, that may affectinsulin sensitivity, use of medications
that are known to inﬂuence glucose metabolism, history of anaphylaxis or
anaphylactoid-like reactions, or a known hypersensitivity to Escherichia coli
derived proteins or anesthetic agents, such as lidocaine or procaine hydro-
chloride (Novocaine; Hospira, Inc., Lake Forest, IL). Subjects were provided
with take-home meals and consumed an isocaloric diet, speciﬁcally designed
for each subject, for 48 h before their main study visit to ensure stable dietary
intake. On the morning of the main study visit, subjects attended the Clinical
Research Center after a 12-h fast. An intravenous cannula was placed in each
antecubital fossa, and samples were drawn for baseline laboratory tests. The
skin of the lower abdomen was anesthetized using lidocaine, and by using an
aseptic technique, a core of adipose tissue was obtained using a core biopsy
instrument. The tissue sample was immediately placed in a cryotube and
frozen in liquid nitrogen at the bedside. After baseline laboratory tests and
baseline hAT biopsy, an intravenous bolus of metreleptin (dose 0.01 mg/kg
body weight) or placebo (10 mL normal saline) was given by slow intravenous
injection .1 min. The subject rested in supine position. Thirty minutes later,
the adipose tissue biopsy was repeated for metreleptin signaling experiments
in hAT, and a blood sample was taken for metreleptin signaling experiments in
hPBMCs. Serum and hAT samples were stored in liquid nitrogen in batches
until later analysis. For the in vivo metreleptin signaling study, we performed
experiments with hAT and hPBMCs before and after a bolus of metreleptin
was administered to six lean (BMI 23.7 + 0.66 kg/m
2) and six obese (BMI
35.42 + 5.7 kg/m
2) men. There was no difference in LBP (lean 33.2 + 6.38,
obese 31.48 + 6.1, control 25.85 + 3.98 mg/mL, P = 0.07) or age (lean 41 + 13.3,
obese 43.3 + 10.78, control 33.17 + 14.12 years, P = 0.37) between the groups.
Subjects in the lean group had lower waist circumference (87 + 5.68 vs. 111.8 +
12 cm, P = 0.004) and leptin levels (2.94 + 3.16 vs. 11.3 + 9.28 ng/mL, P = 0.04)
compared with the obese group at baseline. All subjects provided written in-
formed consent to participate, and the study was approved by the institutional
review board at BIDMC.
Laboratory studies
Ex vivo metreleptin signaling study
hAT—For the ex vivo hAT metreleptin signaling study, we used discarded hAT
from subjects undergoing laparoscopic adjustable gastric band, liposuction,
or abdominoplasty at the BIDMC. The age and BMI of the subjects, but no other
identiﬁable information, were recorded. Explants were solubilized for analysis
of phosphorylation of signaling proteins as described previously (7).
hPBMCs—The hPBMCs were isolated as described previously (8).
In vitro metreleptin signaling study
Human primary adipocyte culture. SubcutaneousandomentalhATsamples
were obtained from lean (aged 35–41 years, BMI 22–25 kg/m
2) and obese (aged
34–48 years, BMI 39–50 kg/m
2) men and women, respectively. The human pri-
mary adipocyte (hPA) culture was performed as described previously (9).
Protein extraction and Western blotting. Protein extraction and Western
blotting were performed as described previously (10).
Gene Expression Omnibus datasets analysis of published data. To
compare expression of inhibitors of leptin signaling in hAT from lean and obese
subjects, including SOCS3 and PTP1B, we performed a search of publicly
available data on the Gene Expression Omnibus datasets website (11) using the
search terms “adipose tissue” and “adipocyte.” We excluded nonhuman data-
sets. We searched the results for datasets comparing gene expression proﬁles in
lean and obese humans. We found one dataset with readily available data that
matched our search criteria. We extracted gene expression data for SOCS3 and
PTP1B from this and compared expression levels in lean and obese subjects.
Detection of antileptin antibodies and their functional/biochemical
activity
Levels of serum antileptin antibodies. Levels of serum antileptin anti-
bodies were determined with an in-house developed colorimetric sandwich
enzyme–linked immunosorbent assay (ELISA). In brief, 50 mL metreleptin at
a ﬁnal concentration of 10 mg/mL in PBS, pH 7.4, was plate-bound to a 96-well
ELISA plate (PBI International SpA, Milano, Italy). After 16 h at 4°C, the plates
were extensively washed with PBS-0.05% Tween 20, blocked with 200 mL PBS/
10% FCS for 2 h, and repeatedly washed. Diluted sera in PBS-0.05% Tween
20/10% FCS (from 1/10 to 1/1,000) were added at 100 mL/well and incubated for
4 h at room temperature. After ﬁve washes, goat anti-human polyvalent im-
munoglobulins, such as alkaline phosphatase–conjugated antibodies (Sigma-
Aldrich, St. Louis, MO), were added 100 mL/well for 1 h. The reaction was
developed with Sigma-Fast p-nitrophenyl phosphate and alkaline phosphatase
substrate (PNPP) (Sigma-Aldrich) and read after 30 min at 405 nm in an ELISA
plate-reader (Bio-Rad Laboratories, Hercules, CA). Standard curves of anti-
leptin antibodies were developed in each assay using an antileptin monoclonal
antibody (mAb) generated in our laboratory (mAb 971212). Quantiﬁcation of
optical density values was performed after extrapolation from standard curves
of known concentration of antileptin antibodies.
Functional activity of antileptin antibodies. The functional activity of
antileptin antibodies was assessed with the human leptin-receptor (hLepR)-
transfectedBAF3cell line,providedbyDr.AriehGertler(TheHebrewUniversity,
Rehovot, Israel). In brief, because hLepR
+BAF3 cell proliferation is leptin-
dependent, hLepR
+BAF3 cells were cultured in ﬂat-bottom 96-well microtiter
plates (Becton-Dickinson Falcon, Franklin Lakes, NJ) at a density of 5 3 10
3
cells/well in a total volume of 100 mL RPMI-1640 medium supplemented with
2% FCS (Hyclone-Pierce; Thermo Fisher Scientiﬁc, Inc., Rockford, IL),
2 mmol/L L-glutamine, 100 units/mL penicillin, and 100 mg/mL streptomycin
(Life Technologies, Inc., Carlsbad, CA). Cells were cultured at 37°C in 100%
humidity and 5% CO2 in the presence of increasing doses of metreleptin
ranging from 0.01 to 10 ng/mL. Puriﬁed IgGs from sera of metreleptin-treated
patients, placebo–treated patients, and healthy controls were added to cells
in all the different conditions at a ﬁnal concentration of 50 mg/mL. After 48 h,
[
3H]thymidine (0.5 mCi/well) (Perkin-Elmer, Milano, Italy) was added to the
cultures, and cells were harvested after 12 h. Radioactivity was measured with
a b-cell plate scintillation counter (Wallac, Gaithersburg, MD). As standard of
leptin neutralization, anti-human leptin mAb 971212 was used at increasing
concentrations usually from 0.1 to 25 mg/mL.
Capacity of antileptin IgGs at the biochemical level. We also assessed at
the biochemical level the capacity of antileptin IgGs, isolated from leptin or
placebo-treated subjects and healthy controls, to affect LepR signaling in BAF3
cells. In brief, hLepR
+BAF3 cells were incubated for 1 h at 37°C with
recombinant leptin at 2 ng/mL in the presence or absence of IgGs (50 mg/mL)
puriﬁed from leptin- or placebo-treated subjects and healthy controls. After
a 1-h incubation, cell lysates were generated to perform Western blotting
analyses for STAT3 phosphorylation as a readout of LepR signaling.
Immunocytochemistry. Immunodetection was performed as described pre-
viously (12).
Blood sample measurements. Leptin and LBP were analyzed by ELISA as
described previously (13). Free leptin was measured using radioimmunoassay
for study (Linco Research, Inc., St. Charles, MO; sensitivity, 0.5 ng/mL; co-
efﬁcient of variation [CV], 6–7%) and by immunoradiometric assay for study
(Diagnostics Systems Laboratory [DSL], Webster, TX; sensitivity, 0.1 ng/mL;
CV, 3.7–6.6%). First, 100 mL of unknown serum samples were incubated at
37°C in a water bath for 2 h; 100 mL polyethelene glycol (Immucor, Inc.
Norcross, GA) was then added to standards, subjects, and unknowns, vortexed
for 1 min, and allowed to sit at room temperature for 10 min. Standards, sam-
ples, and subjects then were centrifuged for 15 min at 1,600 rpm; 50 mLs u -
pernatant was used from standards, subjects, and samples in duplicate to
measure free leptin by radioimmunoassay. All samples were run in one assay to
eliminate interassay variability.
Cytokinesandinﬂammatorymarkersweremeasuredinserumorplasmausing
commercially available ELISAs: tumor necrosis factor-a (Quantikine HS; R&D
Systems, Minneapolis, MN; sensitivity, 0.06 pg/mL; CV, 5.3–8.8%), soluble tumor
necrosis factor receptor (sTNFR)-I (Quantikine; R&D Systems; sensitivity, 3 pg/mL;
CV, 2.7–6.9%), sTNFR-II (Quantikine; R&D Systems; sensitivity, 1 pg/mL; CV,
1.6–2.5%), interleukin (IL)-10 (Amersham Biosciences, Buckinghamshire, UK;
high sensitivity, 0.1 pg/mL; CV, 10%), soluble intracellular adhesive molecule-1
(Quantikine; R&D Systems; sensitivity, 0.35 ng/mL; CV, 4.8–10.1%), C-reactive
protein (CRP) (DSL; sensitivity, 1.6 ng/mL; CV, 1.7–3.9%), and IL-6 (Quantikine;
R&D Systems; sensitivity, 0.04 pg/mL; CV, 6.9–7.8%).
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placebo-andmetreleptin-treated subjectsonchangeinstudyvariablemeasures
over time were determined using repeated-measures analysis, allowing for use
of all available data. P values for difference between groups at baseline and
each follow-up were determined by one-way ANOVA. P values for difference
within group at baseline and each follow-up were determined by one-way
ANOVA followed by a least signiﬁcant difference test. Pearson correlation
coefﬁcients were calculated between changes of study variables. All data were
presented as means 6 SE. P , 0.05 was considered statistically signiﬁcant.
Intention-to-treat analysis revealed similar results (data not shown). For the in
vivo signaling study, baseline comparisons among the three groups were made
using a nonparametric Kruskal-Wallis test. The ratios of phosphorylated pro-
tein to total protein were compared before and 30 min after metreleptin bolus,
using a nonparametric, paired Wilcoxon signed rank test. To compare pSTAT3
change between lean and obese subjects, the fold change was compared be-
tween the groups using a Wilcoxon rank sum test. For the ex vivo and the in
vitro signaling study, data were analyzed with one-way ANOVA followed by
post hoc test for multiple comparisons. Analyses were carried out using SPSS
(version 11.5, SPSS, Inc., Chicago, IL) and SAS (version 9; SAS Institute, Inc.,
Cary, NC).
RESULTS
Clinical study I: Body weight, metabolic, and immune
responses to metreleptin versus placebo treatment in
obese hyperleptinemic subjects with diabetes. Cir-
culating leptin levels increased signiﬁcantly in men
and women treated with metreleptin over the 4-month
study period (Table 1, Supplementary Appendix 1). Non-
neutralizing antileptin antibodies developed with increasing
titers, and LBP levels decreased less in metreleptin-treated
subjects compared with placebo-treated subjects. BMI
remained unchanged throughout the study in both treat-
ment groups. Free leptin levels were similar in both treat-
ment groups at baseline but increased signiﬁcantly in
subjects treated with metreleptin despite the presence of
antibodies against metreleptin. Although the development
of antileptin antibodies was signiﬁcantly and positively
correlated with the increase in total circulating leptin
levels (r = 0.99, P , 0.0001), circulating free leptin levels
(r = 0.44, P = 0.012, SI 2) were also increased. This indi-
cates that increasing doses of leptin can break through
the resistance caused by increasing binding of leptin by
l e p t i na n t i b o d i e s .T h ei n c r e a s ei nf r e el e p t i nl e v e l st o
;48.4 ng/mL was not associated with any signiﬁcant dif-
ferential weight loss or changes in inﬂammatory markers
in metreleptin-treated patients and resulted in only a small
but differential improvement in glycemic control (HbA1c
from 8.01 6 0.93 to 7.96 6 1.12, P = 0.03). Changes of
leptin and free leptin levels were not correlated with
changes of body weight or inﬂammatory markers stud-
ied (Table 2). Baseline TNFR-II and monocyte chemo-
attractant protein-1 levels were relatively similar at
baseline in both treatment groups but increased in men
and women treated with metreleptin. By contrast, IL-6,
IL-10, CRP, sTNFR-I, and soluble intracellular adhesive
molecule-I did not change signiﬁcantly in any group
(Table 1).
Laboratory study I: Agonistic/stimulatory activity of
antileptin antibodies generated during metreleptin
administration. We asked whether the antibodies pro-
duced after treatment with metreleptin in clinical study I
were able to affect (stimulate or neutralize) leptin-related
proliferation and intracellular signaling. Thus, we used the
BAF3 cell lines after transfection with the long form of the
human leptin receptor (hLepR
+BAF3). First, we developed
standard curves of antileptin antibodies using an antileptin
mAb generated in the laboratory (Supplementary Appendix
2A). Antibodies isolated from metreleptin-treated obese
subjects were able to stimulate proliferation up to ;50-fold
more than leptin alone but only at lower leptin concen-
trations (Fig. 1A). On the contrary, no additional stimulatory
effect was observed in the same subjects before treatment,
in the placebo-treated subjects, or when using IgGs from
normal subjects (Fig. 1B and C). These functional effects
were also analyzed at the signaling level in terms of STAT3
phosphorylation. IgGs from metreleptin-treated obese sub-
jects signiﬁcantly increased p-STAT3 levels (Fig. 1D, Sup-
plementary Appendix 2B), whereas no effect was observed
after addition of either placebo-treated IgGs or IgGs isolated
from normal controls (Fig. 1E and F, Supplementary
Appendix 2B). These results suggest that metreleptin
treatment results in the production of antileptin anti-
bodies that are not neutralizing but may demonstrate minor
agonistic activities on hLepR measured both as increased
proliferation of a leptin-dependent cell line and as increased
hLepR-mediated STAT3 signaling. The stimulatory effect of
these antibodies is small, however, and easily overridden by
relatively higher leptin doses.
Clinical study II: In vivo metreleptin signaling in hAT
and hPBMCs from lean and obese subjects. To study
whether intracellular signaling pathways are differentially
activated (and thus underlie leptin resistance) in leptin-
sensitive lean subjects versus leptin-resistant obese subjects
in response to increasing leptin levels similar to those seen
in clinical trials, we performed in vivo signaling experi-
ments. In vivo metreleptin administration (0.01 mg/kg)
induced an approximately 3.2-fold increase in p-STAT3
at 30 min versus baseline in both hAT (Supplementary
Appendix 3A) and hPBMCs (Supplementary Appendix 3B),
with no signiﬁcant difference in p-STAT3 levels from lean
versus obese subjects.
Laboratory study II: Comparative evaluation of ex
vivo metreleptin signaling in hAT and hPBMCs from
lean and obese subjects
No differential activation of STAT3 signaling by ex
vivo metreleptin administration in hAT and hPBMC.
Dose-response curves showed that administration of up to
50 ng/mL metreleptin for 30 min signiﬁcantly induced
phosphorylation of STAT3 in subcutaneous and omental
hAT from obese male and female subjects (Fig. 2A and B).
These results were similar to what was observed in hAT
and hPBMCs after in vivo metreleptin administration
(Supplementary Appendix 3A and B). Similar to in vivo
observations, there was no signiﬁcant difference in p-STAT3
expression in hAT from obese versus lean subjects (Fig. 2C
and D). The phosphorylated form of STAT3 was in-
creased in metreleptin-stimulated hPBMCs (Fig. 2E and F)
compared with control, showing that activation was
evident as early as 5 min after ex vivo stimulation with
metreleptin.
No differential activation of MAPK signaling by
ex vivo metreleptin administration in hAT. Ex vivo
metreleptin administration stimulated activation of MAPK
by ;3.1-fold in hAT (Fig. 2G) from obese male and female
subjects. There was no difference in MAPK activation
from subcutaneous versus omental, male versus female,
and obese versus lean subjects.
No differential expression of inhibitors of ex vivo
metreleptin signaling in hAT. We observed no activa-
tion of SOCS3 by ex vivo metreleptin administration in hAT
(Supplementary Appendix 4). There was no difference in
SOCS3 activation from subcutaneous versus omental, male
versus female, and obese versus lean subjects.
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Clinical study I: Study variables for obese, diabetic subjects taking placebo (n = 21) or metreleptin (n = 50) at baseline and 4 and
16 weeks of follow-up and % change in study variables from baseline to 16 weeks
Variable
Placebo-treated
a Leptin-treated
n Mean 6 SE % n Mean 6 SE % P value
b P value
c
Female 42.9 42.0
BMI 0.80
Baseline 21 32.8 6 0.7 50 32.7 6 0.5 0.84
Week 4 21 32.6 6 0.7 47 32.5 6 0.5 0.85
Week 16 19 32.8 6 0.7 45 31.9 6 0.5 0.36
Change after 16 wk 19 20.5 6 0.2 21.6 45 20.7 6 0.1 22.1 0.43
Leptin (ng/mL) ,0.0001
Baseline 18 38.0 6 6.4 48 35.2 6 3.5 0.27
Week 4 18 35.5 6 6.8 49 430.6 6 47.4 ,0.0001
Week 16 20 36.8 6 6.5 48 987.1 6 50.1 ,0.0001
Change after 16 wk 18 23.1 6 3.2 28.2 47 957.2 6 50.4 2,721 ,0.0001
LBP (ng/mL) 0.04
Baseline 20 25.3 6 1.7 49 25.0 6 1.2 0.88
Week 4 19 23.5 6 1.4 49 24.4 6 1.2 0.77
Week 16 21 22.7 6 1.4 49 24.4 6 1.1 0.35
Change after 16 wk 20 22.2 6 1.1 28.8 48 20.4 6 0.5 21.5 0.07
Free leptin (ng/mL) 0.002
Baseline 15 15.8 6 3.3 32 22.6 6 4.7 0.37
Week 4 7 13.9 6 4.2 26 30.0 6 6.0 0.16
Week 16 16 14.5 6 3.9 33 61.6 6 7.8 0.0002
Change after 16 wk 11 21.3 6 1.6 28.1 21 53.2 6 11.5 236.0 0.002
Antibody titer (mg/mL) 0.0009
Baseline 7 0.0 6 0.0 16 5.3 6 4.0 0.41
Week 4 1 0.0 6 0.0 8 33.5 6 11.4 0.56
Week 16 6 0.0 6 0.0 14 52.3 6 2.7 ,0.0001
Change after 16 wk 4 0.0 6 0.0 0 5 52.7 6 3.9 987.4 0.0001
IL-6 (pg/mL) 0.62
Baseline 20 3.2 6 0.2 49 3.7 6 0.4 0.25
Week 4 19 3.7 6 0.2 49 3.6 6 0.5 0.78
Week 16 21 3.5 6 0.3 49 3.6 6 0.5 0.78
Change after 16 wk 20 20.1 6 0.6 23.2 48 0.2 6 0.3 6.4 0.59
CRP (mg/L) 0.93
Baseline 20 9,356 6 2,059 48 9,138 6 1,172 0.95
Week 4 19 9,200 6 2,026 49 9,702 6 1,215 0.87
Week 16 21 8,609 6 2,013 49 9,512 6 1,158 0.62
Change after 16 wk 20 2555 6 1,013 25.9 47 448 6 883 4.9 0.52
sTNFR-I (pg/mL) 0.31
Baseline 20 1,058 6 63.1 49 1,129 6 45.7 0.43
Week 4 19 1,056 6 68.0 50 1,147 6 51.6 0.37
Week 16 21 1,051 6 69.7 49 1,134 6 48.2 0.29
Change after 16 wk 20 28.6 6 32.6 20.8 48 23.7 6 23.8 2.1 0.47
sTNFR-II (pg/mL) 0.09
Baseline 20 2,089 6 186.9 49 2,470 6 111.0 0.08
Week 4 19 2,132 6 217.7 50 2,493 6 118.1 0.14
Week 16 21 2,132 6 172.1 49 2,533 6 111.3 0.04
Change after 16 wk 20 24.4 6 63.9 20.2 48 84.5 6 57.1 3.4 0.39
sICAM-1 (ng/mL) 0.31
Baseline 20 298.4 6 12.5 49 313.2 6 14.1 0.54
Week 4 18 282.8 6 13.0 48 305.6 6 14.1 0.38
Week 16 21 288.6 6 12.4 48 317.7 6 14.0 0.20
Change after 16 wk 20 27.0 6 8.4 22.3 47 21.4 6 9.8 20.4 0.77
IL-10 (pg/mL) 0.42
Baseline 11 10.4 6 2.0 27 8.9 6 1.0 0.56
Week 4 9 9.2 6 2.5 18 8.5 6 1.1 0.91
Week 16 13 9.2 6 1.6 25 9.2 6 1.2 0.94
Change after 16 wk 8 0.2 6 0.4 2.3 19 0.9 6 1.2 10 0.71
sICAM, soluble intracellular adhesive molecule.
aData presented are on treatment. The number of subjects is variable because of occasional
missing blood test results from a few subjects in a small numbers of analytes as shown. The change after 16 weeks is based on pairwise
difference of subjects who had data available for both baseline and week 16 time points. Means 6 SEs are presented for each variable at each
follow-up visit.
bP values are calculated from one-way ANOVA.
cP values are calculated from repeated-measures analysis evaluating the
change in study variables over time, adjusted for age and sex.
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ex vivo metreleptin administration in hAT and
hPBMC. Ex vivo metreleptin administration stimulated
phosphorylation of AMPK in both subcutaneous and
omental hAT, and hPBMCs from obese female subjects
(Supplementary Appendix 5). We observed no difference
in AMPK activation from subcutaneous versus omental,
obese versus lean, and male versus female subjects.
Laboratory study III: In vitro metreleptin signaling in
subcutaneous and omental hPAs from lean and obese
subjects
No differential activation of STAT3 signaling by
in vitro metreleptin administration in hPA. In vitro
metreleptin administration signiﬁcantly induced phosphory-
lation of STAT3 by ;2.1-fold at 10 min with a trend toward
greater induction at 20–40 min (Fig. 3A and B). A consider-
able amount of p-STAT3 in metreleptin-treated cells, but only
background levels of p-STAT3 in control cells, was detected
in both subcutaneous and omental hPA (Fig. 3C). However,
these effects were totally blocked by pretreatment with
AG490, a STAT3 inhibitor (Fig. 3D), suggesting that metre-
leptin stimulation activates STAT3 signaling in hPA. In
addition, we observed nuclear translocation of STAT3 by
in vitro metreleptin administration in a dose-dependent
manner (Supplementary Appendix 6). Metreleptin signaling
pathways in hPA were saturable at a level of ;50 ng/mL,
and these results are consistent with those observed in hAT
in vivo and ex vivo. There were no signiﬁcant differences
in STAT3 activation from subcutaneous versus omental,
male versus female, and obese versus lean subjects.
No differential activation of AMPK signaling by in
vitro metreleptin administration in hPA. In vitro
metreleptin administration increased AMPK phosphorylation
by ;2.5-fold in both subcutaneous and omental hPA from
male and female subjects (Fig. 3E). We observed no differ-
ences in AMPK phosphorylation from subcutaneous versus
omental, male versus female, and obese versus lean subjects.
No differential expression of inhibitors of metrelep-
tin signaling in hPA. We observed no early activation of
SOCS3 by in vitro metreleptin administration in hPA (Fig.
3F). In addition, we observed no differences in expression
of inhibitors from subcutaneous versus omental, obese
versus lean, and male versus female subjects.
Downregulation of in vitro metreleptin-stimulated
STAT3 signaling by ER stress in hPA. Stimulation of
the cells with metreleptin led to a marked increase in
phosphorylation of STAT3, but when challenged with ER
stress (tunicamycin and dithiothreitol), the metreleptin-
activated STAT3 phosphorylation was abolished totally
(Supplementary Appendix 7). We observed no differences
in ER stress–mediated STAT3 phosphorylation from sub-
cutaneous versus omental, male versus female, and obese
versus lean subjects.
Laboratory study IV: Gene Expression Omnibus data-
sets analysis of published data on expression of inhib-
itors of metreleptin signaling. To validate our in vivo,
ex vivo, and in vitro metreleptin signaling data, we used
publicly available datasets to examine expression of
potential inhibitors of leptin signaling in hAT from lean
and obese nondiabetic humans. We analyzed a dataset
TABLE 2
Clinical study I: Pearson correlation coefﬁcients of the changes in study variables before and after 16 weeks of treatment
Change in variable Leptin Free leptin Leptin antibody LBP IL-6 CRP sTNFR-I sTNFR-II MCP1 sICAM-1 IL-10
BMI
r 20.08 20.17 20.11 0.11 0.20 0.00 20.04 20.02 0.22 0.10 20.18
P value 0.531 0.372 0.812 0.395 0.122 0.991 0.754 0.866 0.113 0.432 0.424
Leptin
r 0.44 0.99 0.00 0.02 20.17 0.00 20.07 0.02 20.16 20.02
P value 0.012 ,0.0001 0.975 0.9 0.16 0.999 0.583 0.85 0.203 0.932
Free leptin
r 0.22 20.17 20.13 20.22 20.04 0.18 0.16 20.05 0.29
P value 0.601 0.363 0.494 0.236 0.808 0.325 0.4 0.782 0.274
Leptin antibody
r 0.31 0.09 20.25 0.14 0.15 0.18 20.07 20.13
P value 0.416 0.827 0.521 0.728 0.699 0.641 0.853 0.806
LBP
r 0.14 0.44 0.25 0.18 20.08 0.26 20.13
P value 0.241 0.0002 0.043 0.132 0.522 0.031 0.503
IL-6
r 0.30 0.21 0.25 0.07 0.20 0.22
P value 0.015 0.081 0.041 0.619 0.109 0.27
CRP
r 0.43 0.47 0.05 0.49 0.26
P value 0.0003 ,0.0001 0.723 ,0.0001 0.186
sTNFR-I
r 0.62 0.09 0.40 0.50
P value ,0.0001 0.513 0.0007 0.008
sTNFR-II
r 0.22 0.52 0.66
P value 0.091 ,0.0001 0.0002
sICAM-1
r 0.43
P value 0.028
MCP, monocyte chemoattractant protein; sICAM, soluble intracellular adhesive molecule.
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adipocytes from 20 lean and 19 obese nondiabetic Pima
Indians (14), and there was no signiﬁcant difference in the
expression levels of PTP1B or SOCS3.
DISCUSSION
Several open-label trials have demonstrated that adminis-
tering metreleptin to correct overt hypoleptinemia signiﬁ-
cantly improves the metabolic abnormalities and insulin
resistance in patients with congenital lipodystrophy and
insulin resistance (1). Likewise, randomized placebo-
controlled trials in patients with human immunodeﬁciency
virus–induced lipodystrophy and the metabolic syndrome
who are also hypoleptinemic, although less so than sub-
jects with congenital lipodystrophy, have shown signiﬁcant,
albeit less pronounced, effects of metreleptin (15,16).
In contrast, obese hyperleptinemic subjects do not respond
to exogenously administered leptin (15,16). We studied
whether metreleptin administration would be effective
in hyperleptinemic obese subjects with garden variety
insulin resistance and diabetes who are considered leptin-
resistant or -tolerant. We observed only minor improve-
ments in the glycemic control of hyperleptinemic/diabetic
subjects in this randomized trial, which, albeit statistically
signiﬁcant, are one order of magnitude less pronounced
than those observed in hypoleptinemic, lipodystrophic sub-
jects and apparently are not of major clinical importance (2).
Final body weight and levels of inﬂammatory markers
remained completely unaltered in metreleptin-treated
hyperleptinemic obese diabetic subjects. This lack of metre-
leptin’se f ﬁcacy is consistent with a state of “resistance”
or “tolerance” to leptin action, deﬁned as an inability of
increasing leptin levels to reduce body weight in obese
individuals (17). This is the ﬁrst study in obese diabetic
subjects that proves the existence of clinical leptin re-
sistance or tolerance similar to the only prior study in
obese nondiabetic subjects (17). Moreover, this study dem-
onstrated no inﬂammatory response to leptin, with only a
minor glycemic response of no apparent clinical signiﬁ-
cance. Thus, we initiated studies to elucidate mechanisms
underlying leptin resistance or tolerance.
We ﬁrst explored whether mechanisms similar to those
involved in other hormone resistance syndromes, such as
the increase in binding protein levels, the development of
antibodies, the presence of a saturable signaling system, or
the presence of in vivo or ex vivo signaling inhibitors in
humans, may underlie leptin resistance. A novel ﬁnding
of this study was that LBP, the extracellular cleaved part of
the long isoform of the leptin receptor, and the titers of
antileptin antibodies increased signiﬁcantly in response to
metreleptin administration, but not in response to placebo
administration. We previously demonstrated that short-
term caloric deprivation (72 h) signiﬁcantly decreases leptin
levels but signiﬁcantly increases LBP by .100% (18). The
current study shows that LBP levels increase in response
to several months of pharmacologic metreleptin versus
placebo treatment. We also observed for the ﬁrst time the
development of non-neutralizing, leptin–binding antibodies,
the titers of which increased in the circulation over time
FIG. 1. Laboratory study I. Agonistic/stimulatory activity of antileptin antibodies generated during metreleptin administration. A–C: The func-
tional activity of antileptin antibodies in hLepR
+BAF3 cells was as described in detail in RESEARCH DESIGN AND METHODS. ■, Leptin + IgG posttreatment;
◆, Leptin + IgG pretreatment. D–F: The biochemical level of the capacity of antileptin IgGs in hLepR
+BAF3 cells was studied as described in detail in
RESEARCH DESIGN AND METHODS. All density values for each protein band of interest are expressed as a fold increase. Data were analyzed using one-way
ANOVA followed by post hoc test for multiple comparisons. Values are means (n =6 )6 SD. Means with different letters are signiﬁcantly different,
P < 0.05. L.N.C., lean normal control.
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distinct possibility exists that other formulations of leptin
that do not have the amino acid (methionine) substitution,
which in the case of metreleptin was added to improve
protein folding, but have full sequence homology with
human leptin may not induce leptin antibodies; this pos-
sibility remains to be studied. In addition, because phar-
macologic metreleptin doses (;0.2 mg/kg in the current
study) may have different effects than physiologic doses in
terms of generating antibodies (C.S.M., unpublished data),
future placebo–controlled randomized studies involving
metreleptin administration in lower, physiologic replace-
ment doses are needed. In any case, the apparent impor-
tance of this novel ﬁnding is that the majority of circulating
leptin is bound to antileptin antibodies, whereas only a
small fraction of circulating leptin is free leptin. Thus, we
proceeded to explore whether this observation could also
be of clinical signiﬁcance.
FIG. 2. Laboratory study II. Comparative evaluation of ex vivo metreleptin signaling in hAT and hPBMCs from lean and obese subjects. Ex vivo
metreleptin administration in hAT and hPBMCs was performed as described in detail in RESEARCH DESIGN AND METHODS. hAT (A–D) and hPBMCs (E)
were incubated and stimulated with or without ex vivo metreleptin at the indicated concentrations for 30 min. F: hPBMCs were incubated and
stimulated with or without ex vivo metreleptin at the indicated times. G: hAT was incubated and stimulated with or without ex vivo metreleptin at
the indicated concentrations for 30 min. All lysates were examined by Western blotting as described in detail in RESEARCH DESIGN AND METHODS.A l l
density values for each protein band of interest are expressed as a fold increase. Data were analyzed using one-way ANOVA followed by post hoc
test for multiple comparisons. Values are means (n =3 )6 SD. Means with different letters are signiﬁcantly different, P < 0.05. OM, omental; SC,
subcutaneous.
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free leptin increased and remained relatively higher (i.e.,
at levels ;40–50 ng/mL) in metreleptin-treated subjects.
Although these levels are higher than the putative threshold
for saturating the blood-brain–barrier leptin transport sys-
tem (19,20), circulating free leptin levels did not correlate
with weight loss, indicating clinical ineffectiveness of free
leptin levels in the 40–50 ng/mL range. Thus, we decided to
study whether metreleptin administration in doses within or
above the physiologic leptin range, and encompassing the
;50 ng/mL levels seen in our clinical studies described, can
differentially activate signaling pathways in humans in vivo,
ex vivo, and in vitro. It has been shown that leptin induces
STAT3 phosphorylation in various mouse cell lines and
tissues and is generally accepted that this represents a ma-
jor signaling pathway through which leptin exerts its
actions (7, 21–26). Despite minor differences in the timing
of signaling pathway activation, we observed no major
FIG. 3. Laboratory study III. In vitro metreleptin signaling in subcutaneous (SC) and omental (OM) hPA from lean and obese subjects. In vitro
metreleptin administration in hPA was performed as described in detail in RESEARCH DESIGN AND METHODS. A: Cells were treated with metreleptin
at the indicated concentrations for 30 min. B: Cells were treated with metreleptin at the indicated times. C: Cells were treated with metreleptin
(50 ng/mL) for 30 min. Immunodetection was carried out as described in detail in RESEARCH DESIGN AND METHODS. All pictures were 340 magniﬁcation.
D: Cells were pretreated with the STAT3 inhibitor AG490 (AG, 1 mmol/L) for 1 h, followed by treatment with 50 ng/mL metreleptin for 30 min.
E and F: Cells were treated with metreleptin at the indicated concentrations for 30 min. All lysates were examined by Western blotting as de-
scribed in detail in RESEARCH DESIGN AND METHODS. All density values for each protein band of interest are expressed as a fold increase. Data were
analyzed using one-way ANOVA followed by post hoc test for multiple comparisons. Values are means (n =3 )6 SD. Means with different letters are
signiﬁcantly different, P < 0.05. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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sponse to metreleptin administration in the human pe-
ripheral tissues studied in vivo, ex vivo, or in vitro. We
observed no differences in leptin-activated signaling path-
ways when comparing obese versus lean subjects or men
versus women in vivo, ex vivo, or in vitro. More important,
metreleptin signaling pathways were saturable at a level of
;50 ng/mL, suggesting that above that level, i.e., the level
clinically seen in obese subjects at baseline, no additional
signaling effect can be observed. This explains the effec-
tiveness of metreleptin in subjects with very low circulating
leptin levels and the tolerance to metreleptin’s actions when
the baseline circulating level is closer to the 40–50 ng/mL
range.
We then focused on ER stress, which has recently been
shown to play a role in the development of leptin re-
sistance in the hypothalamus of rodents (2). It has been
suggested that ER capacity is directly related to leptin
sensitivity (3,4,27), and thus, it has been proposed that ER
stress reversal could be used as a strategy to sensitize
obese mice and, by extension, humans to leptin. These
previous studies have shown that the reduction in ER
function creates ER stress, blocks leptin action, and gen-
erates leptin resistance in mice, suggesting that ER stress
provides a potential mechanism for the development of
leptin resistance in which increased ER stress antagonizes
and inhibits leptin-mediated STAT3 signaling at a step
upstream of STAT3 phosphorylation (27). Because ER
stress cannot yet be studied in humans in vivo, we per-
formed in vitro metreleptin signaling studies in hPAs to
explore whether ER stress could underlie the development
of leptin resistance in human primary cells. We report for
the ﬁrst time that ER stress limits leptin signaling in hPAs in
vitro, indicating that ER stress may induce leptin resistance
in humans similar to induction of leptin resistance in mice
in vivo (3,4) and suggesting that improving ER stress could
be used as a strategy to sensitize not only obese mice (3,27)
but also humans to metreleptin. Because in vivo leptin
actions may differ in comparison with in vitro, studies of in
vivo leptin signaling in humans are needed to prove or
disprove this hypothesis, but it is currently impossible to
perform human in vivo ER stress studies.
The blinded and simultaneous administration of metre-
leptin or placebo in the current study provides a clear and
contemporaneous assessment of the role of metreleptin in
regulating body weight, metabolic, and immune function in
obese diabetic individuals. It could be argued that metre-
leptin may have different actions in the pharmacologic
range (as used in the current study) than in the physiologic
range, in terms of generating antileptin antibodies or pos-
sibly by resulting in differential downregulation of leptin
receptors. It is unlikely that the latter is the case in the
current study because we observed an increase in LBP,
which reﬂects an increased number of cell surface recep-
tors (18). The possible differences between the effects
of pharmacologic and physiologic doses of metreleptin,
however, need to be studied by future well-designed clin-
ical trials in which signiﬁcant weight loss will be induced
and replacement dose of metreleptin will be administered
and studied in relation to weight maintenance. Finally,
although it is difﬁcult to perform in vivo time course sig-
naling experiments in humans, this is an area that also
needs to be addressed in future studies. Future in vivo
leptin signaling studies involving additional signaling
pathways and other peripheral human tissues are also
needed. However, leptin signaling in central nervous
system tissues (i.e., hypothalami of humans) cannot be
studied in vivo or ex vivo, and thus we and others have
initiated indirect studies of leptin’s actions in the brain
using functional magnetic resonance imaging techniques.
It is also possible that inducers of leptin resistance other
than those in the current study may exist in humans and
corresponding leptin sensitizers, if any, remain to be
identiﬁed.
We believe that beginning to elucidate the mechanisms
underlying the physiologic and pharmacologic actions
of metreleptin, using studies with direct relevance to
humans as those presented in this article, offers distinct
advantages over the studies in rodents that have been
published to date. These initial translational studies in
humans are of direct potential clinical and therapeutic
signiﬁcance.
In summary, in obese patients with diabetes, metreleptin
administration for 16 weeks did not alter body weight or
circulating inﬂammatory markers but reduced HbA1c
marginally. Furthermore, total leptin, LBP, and antileptin
antibody levels increased, limiting free leptin availability
and resulting in circulating free leptin levels of ;50 ng/mL.
These data identify several steps mediating leptin “toler-
ance” in humans. Most important, we demonstrate for the
ﬁrst time the saturable nature of leptin signaling pathways
in humans and the inhibition of leptin signaling by envi-
ronmental factors inducing ER stress that contribute sig-
niﬁcantly to the development of leptin tolerance in obese
humans. The mechanisms reported lend themselves to
future studies with an ultimate goal of identifying and
overcoming leptin resistance in the path toward de-
veloping novel therapies for the treatment of excess adi-
posity and associated abnormalities in humans.
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